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A B S T R A C T 
Introduction: In Hong Kong, universal combined 
first-trimester screening for Down’s syndrome was 
started as a ‘free service’ in July 2010. Non-invasive 
prenatal testing was available as a self-financed 
item in August 2011. This study aimed to determine 
whether the introduction of non-invasive prenatal 
testing as a contingent approach influenced the 
indications for invasive prenatal diagnosis and the 
consequent prenatal detection of Down’s syndrome. 
Methods: This historical cohort study was 
conducted at the Prenatal Diagnosis Clinic of Queen 
Elizabeth Hospital in Hong Kong. We compared 
the indications for invasive prenatal diagnosis and 
prenatal detection of Down’s syndrome in singleton 
pregnancies 1 year before and 2 years following 
the availability of non-invasive prenatal testing as 
a contingent test after a positive aneuploidy test. 
All pregnant women who attended our hospital 
for counselling about universal Down’s syndrome 
screening between August 2010 and July 2013 were 
recruited. 
Results: A total of 16 098 women were counselled. 
After the introduction of non-invasive prenatal 
testing, the invasive prenatal diagnosis rate for 
a positive aneuploidy screening reduced from 
77.7% in 2010-11 to 68.8% in 2012-13. The new 
combined conventional plus non-invasive prenatal 
testing strategy was associated with a lower false-
positive rate (6.9% in 2010-11 vs 5.2% in 2011-12 
and 4.9% in 2012-13). There was no significant 
increase in invasive prenatal diagnosis for structural 
Effect of non-invasive prenatal testing as a 
contingent approach on the indications for 
invasive prenatal diagnosis and prenatal 
detection rate of Down’s syndrome
Introduction
Over the last 30 years, there has been a shift in 
clinical practice away from performing an invasive 
New knowledge added by this study
• Introduction of non-invasive prenatal testing (NIPT) decreased overall invasive prenatal diagnosis (IPD) rate 
for a positive aneuploidy screening without affecting the IPD rate for structural anomalies.
• NIPT as a contingent approach does not affect the overall detection rate of fetal Down’s syndrome. 
Implications for clinical practice or policy
• NIPT provides a safe contingent approach for a positive aneuploidy screening. This is particularly relevant in 
centres with a high false-positive rate following conventional screening for Down’s syndrome. 
• Extending the indications of NIPT from high-risk to intermediate- or low-risk women with a view to increasing 
the prenatal detection rate of Down’s syndrome requires further evaluation.
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prenatal diagnosis (IPD) on the basis of maternal 
age to a non-invasive screening method1-5 with 
improving performance.6-12 Initially, the introduction 
ORIGINAL ARTICLECME
anomalies over the years. There was no significant 
trend in the overall prenatal detection rate of 
Down’s syndrome (100% 1 year before vs 89.1% 2 
years after introduction of non-invasive prenatal 
testing). Four (2.6%) of 156 women who underwent 
non-invasive prenatal testing for a screen-positive 
result had a high-risk result for trisomy 21, which 
was subsequently confirmed by invasive prenatal 
diagnosis. There were no false-negative cases. 
Conclusion: The introduction of non-invasive 
prenatal testing as a contingent approach reduced 
the invasive prenatal diagnosis rate for a positive 
aneuploidy screening without affecting the invasive 
prenatal diagnosis rate for structural anomalies or 
the overall detection rate of fetal Down’s syndrome.
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of second-trimester screening (STS) resulted in an 
overall increase in the number of IPD tests, mainly 
amniocentesis, for women aged <35 years with 
screen-positive result.1 The later implementation of 
combined first-trimester screening (cFTS) caused 
a mild and gradual decrease in the number of IPD 
and amniocentesis, but an increase in the number or 
proportion of chorionic villus sampling (CVS) tests.1-3 
The recent introduction of non-invasive prenatal 
testing (NIPT) has resulted in a rapid decrease in the 
number of invasive tests including amniocentesis 
and CVS within a short period of time.5,13,14 Such 
non-invasive testing has a higher sensitivity (95.5-
100% vs 85-90%) and a lower false-positive rate 
(0.002-0.2% vs 3-5%) than traditional non-invasive 
screening methods for Down’s syndrome,6-12 and is 
well accepted by women5 and physicians.15 
 Although not as a free service, NIPT has been 
available in Hong Kong since August 2011. In our 
previously published study,16 we showed that the 
introduction of NIPT as a contingent test resulted 
in a significant decrease in IPD by 16.3% and 
25.6% in the first and second year, respectively. It 
remained unclear, however, whether this change in 
practice affected the overall prenatal detection rate 
of Down’s syndrome and whether the indication for 
IPD because of a scan abnormality was increased. In 
the present study, using the same study population 
as before, we aimed to review all the indications for 
IPD and to determine any alteration in the overall 
prenatal detection of Down’s syndrome before and 
after the introduction of NIPT as a contingent 
approach.
Methods
This historical cohort study was conducted at 
the Prenatal Diagnosis Clinic of Queen Elizabeth 
Hospital, Hong Kong. All pregnant women who 
attended our hospital for counselling on prenatal 
testing for Down’s syndrome between August 2010 
and July 2013 were recruited. The utilisation of 
conventional screening, NIPT, and IPD for Down’s 
syndrome and other aneuploidies in all singleton 
pregnancies were included. Our hospital is one of 
the largest referral public hospitals in Hong Kong 
with around 6000 deliveries a year. This study was 
approved by the Research Ethics Committee of 
Kowloon Central/Kowloon East Cluster, Hong 
Kong. Informed consent was not required for this 
retrospective study. 
 Since 1 July 2010, universal prenatal screening 
for Down’s syndrome with cFTS between 11 weeks 
and 13 weeks and 6 days or STS has been offered 
to all pregnant women after adequate counselling. 
Combined first-trimester screening includes fetal 
nuchal translucency (NT) measurement, and 
free beta–human chorionic gonadotrophin and 
pregnancy-associated plasma protein-A assessment. 
The gestational age is determined by an ultrasound 
examination (crown rump length in the first or head 
biometry in the second trimester) shortly after the 
first antenatal visit. 
 All NT measurements were performed by 
trained midwives and doctors who were Fetal 
Medicine Foundation–certified or accredited as 
maternal fetal medicine (MFM) subspecialists. 
In our hospital, MFM team doctors counselled 
screen-positive (risk ≥1 in 250 in cFTS) women 
about different options including IPD with CVS 
or amniocentesis, or no further prenatal invasive 
testing. After August 2011, the option of self-
financed NIPT was also discussed at the request of 
patients.
 Most commercial NIPT was based on massively 
parallel sequencing with ‘shotgun’ counting of 
all cell-free DNA sequences while others involve 
‘targeted’ counting of specific DNA sequences. A 
usual NIPT report includes the risk for trisomies 21, 
18, and 13. Sex chromosomal or other abnormalities 
are also reported if identified on NIPT. If NIPT 
demonstrated a high risk for trisomy 21, 18 or 13, 
confirmatory  IPD was required. After undergoing 
NIPT in the private sector, the woman would be 
followed up, counselled by doctors, rescanned for 
any structural fetal anomaly and offered an option 
of invasive testing, regardless of the results of NIPT, 
#  Prenatal testing for Down’s syndrome  # 
225Hong Kong Med J  ⎥  Volume 22 Number 3  ⎥  June 2016  ⎥  www.hkmj.org
at no charge. We advised women with fetal NT ≥3.5 
mm or structural abnormalities to undergo IPD 
rather than NIPT given their higher risk of atypical 
chromosome abnormalities that might not be 
picked up by the latter.17 In addition, IPD would be 
offered (a) if first-trimester or routine mid-trimester 
anomaly scan showed an abnormality, (b) for genetic 
diseases like thalassaemia, (c) if there was a positive 
family history, or (d) rarely, if there was maternal 
anxiety after adequate counselling. 
 Chromosome analysis was mainly performed 
by the prenatal diagnostic laboratory of Tsan Yuk 
Hospital and a small proportion at Prince of Wales 
Hospital, Hong Kong. These two laboratories are 
accredited by professional bodies in providing 
prenatal diagnostic tests and serve the local obstetric 
units. Analyses included G-banding chromosome 
analyses and quantitative fluorescence polymerase 
chain reaction for rapid aneuploidy detection. All 
pregnancy outcomes were traced by reviewing 
hospital records or phone contact in women who 
delivered outside this hospital. 
 We determined the number of fetuses and 
newborns with Down’s syndrome prenatally or 
postnatally, the rate of different prenatal tests for 
Down’s syndrome, and the number of IPD that 
were needed to diagnose one fetus with Down’s 
syndrome. We also reviewed the indications for 
IPD and classified them as one of the following 
priorities: high risk for trisomy 21, 18, 13 or other 
aneuploidy on NIPT, increased NT (≥3.5 mm), 
structural anomalies on ultrasound, parental 
carrier of or previous pregnancies with abnormal 
karyotype, positive aneuploidy screening, maternal 
age ≥35 years, or others. If NT was increased and 
cFTS trisomy 21 risk was high, increased NT would 
be selected as the sole indication for IPD.
Statistical analyses
With the use of descriptive statistics and Chi squared 
test for linear trend, the rates of conventional 
screening, NIPT, IPD, and prenatally diagnosed 
Down’s syndrome were compared 1 year before and 2 
years after NIPT introduction. All statistical analyses 
were performed using the Statistical Package for the 
Social Sciences (Windows version 21.0; SPSS Inc, 
Chicago [IL], US).
Results
A total of 16 098 women with singleton pregnancies 
were counselled on prenatal testing for Down’s 
syndrome. Although the total proportion of women 
who underwent screening remained around 97% 
from 2010 to 2013, cFTS increased from 84.4% in 
2010-11 to 90.5% in 2012-13 and STS decreased 
from 12.1% to 7.1% in the same period (P<0.001) 
[Table 1]. With a sharp increase in the use of NIPT 
in the screen-positive group (0%, 0.8%, and 1.9% in 
2010-11, 2011-12, 2012-13, respectively; P<0.001), 
the rate of IPD and CVS dropped from 7.6% and 
4.2% in 2010-11 to 6.0% and 2.5% in 2012-13, 
respectively while the amniocentesis rate fluctuated. 
The actual number of IPD remained similar over the 
TABLE 1.  Trend analysis for number of a variety of tests in women who attended prenatal diagnosis and counselling clinic from August 2010 to July 2013
Total (n=16 098) Aug 2010 – Jul 2011 
(n=4440)
Aug 2011 – Jul 2012 
(n=5904)
Aug 2012 – Jul 2013 
(n=5754)
P value*
Screening 15 632 (97.1%) 4288 (96.6%) 5726 (97.0%) 5618 (97.6%)
cFTS 14 144 (87.9%) 3749 (84.4%) 5188 (87.9%) 5207 (90.5%) <0.001
STS 1488 (9.2%) 539 (12.1%) 538 (9.1%) 411 (7.1%) <0.001
Screened positive 1069 (6.8%) 306 (7.1%) 362 (6.3%) 401 (7.1%) 0.151
cFTS 957 (6.8%) 270 (7.2%) 330 (6.4%) 357 (6.9%)
STS 112 (7.5%) 36 (6.7%) 32 (5.9%) 44 (10.7%)
False positive 1016 (6.5%) 294 (6.9%) 343 (6.0%) 379 (6.7%) 0.142
NIPT for positive cFTS or STS 156 (1.0%) 0 49 (0.8%) 107 (1.9%) <0.001
NIPT positive 4 0 1 3
Reduction in false positive 152 (15.0%) 0 48 (14.0%) 104 (27.4%)
Final false positive (%) 5.5% 6.9% 5.2% 4.9%
IPD 1020 (6.3%) 337 (7.6%) 337 (5.7%) 346 (6.0%) 0.03
Amniocentesis 494 (3.1%) 152 (3.4%) 139 (2.4%) 203 (3.5%) 0.03
CVS 526 (3.3%) 185 (4.2%) 198 (3.4%) 143 (2.5%) 0.04
Abbreviations: cFTS = combined first-trimester screening; CVS = chorionic villus sampling; IPD = invasive prenatal diagnosis; NIPT = non-invasive prenatal 
testing; STS = second-trimester screening
* Chi squared test for linear trend
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years though the rate declined, probably because of 
an increasing number of screenings from 4288 in 
2010-11 to 5618 in 2012-13 (Table 1).
Indications for invasive prenatal diagnosis 
There was a significant decrease in IPD for positive 
aneuploidy screening from 77.7% in 2010-11 to 
68.8% in 2012-13 (P=0.005). There was no significant 
increase in IPD for structural anomalies over the 
years (Table 2). 
Prenatal detection of Down’s syndrome
There was no significant trend in the overall prenatal 
diagnosis/detection rate of Down’s syndrome 
before and after the availability of NIPT (Table 3). 
The number of IPD required to diagnose one case 
of Down’s syndrome decreased from 28 to 16 over 
the same period of time, though the trend was not 
significant, probably because of the small sample 
size (Table 3). There were nine newborn infants with 
Down’s syndrome over the 3 years. In two cases, 
women declined IPD despite a positive Down’s 
syndrome screening result. In another two cases 
that were included in the 45 diagnosed prenatally, 
women chose to continue their pregnancy after IPD 
of Down’s syndrome. The remaining five cases were 
screened negative and diagnosed postnatally (Fig). 
Performance of non-invasive prenatal testing
Four (2.6%) of 156 women who underwent NIPT for 
a screen-positive result (cFTS or STS being 1 in 3, 1 in 
25, 1 in 45 and 1 in 230) were considered at high risk 
for trisomy 21 (increased amount of chromosome 
21 DNA molecules in a maternal sample compared 
with that of a euploid reference sample); all results 
were confirmed on subsequent IPD. One woman 
TABLE 2.  Trend analysis for number of invasive prenatal diagnosis performed from August 2010 to July 2013 with various clinical indications and 
subgroup analysis for screen-positive results and maternal age ≥35 years
Indication for IPD Down’s syndrome 
diagnosed 
Total No. of IPD 
(n=1020)
Aug 2010 – Jul 
2011 (n=337)
Aug 2011 – Jul 
2012 (n=337)
Aug 2012 – Jul 
2013 (n=346)
P value*
Screen-positive results 24 (3.3%) 736 (72.2%) 262 (77.7%) 236 (70.0%) 238 (68.8%) 0.005
Increased NT 21 (26.3%) 80 (7.8%) 13 (3.9%) 37 (11.0%) 30 (8.7%) 0.016
Structural anomaly 4 (3.6%) 110 (10.8%) 33 (9.8%) 38 (11.3%) 39 (11.3%) 0.730
Family history/genetics† 0 40 (3.9%) 11 (3.3%) 16 (4.7%) 13 (3.8%) 0.601
Anxiety 0 50 (4.9%) 18 (5.3%) 9 (2.7%) 23 (6.6%) 0.05
NIPT high risk 4 (100%) 4 (0.4%) 0 1 (0.3%) 3 (0.9%) 0.183
Abbreviations: IPD = invasive prenatal diagnosis; NIPT = non-invasive prenatal testing; NT = nuchal translucency
* Chi squared test for linear trend
† Family history = previous pregnancy or parental carrier
TABLE 3.  Trend analysis for number and prenatal detection rate of Down’s syndrome, and number of invasive prenatal diagnosis required to diagnose 
one DS case
Total Aug 2010 – Jul 
2011
Aug 2011 – Jul 
2012
Aug 2012 – Jul 
2013
P value*
DS cases (risk in screened population) 58 (1 in 304) 12 (1 in 370) 22 (1 in 311) 24 (1 in 262) 0.447
Prenatally diagnosed or detected DS cases (% of DS cases)† 53 (91.4%) 12 (100.0%) 19 (86.4%) 22 (91.7%) 0.399
No. of IPD needed to diagnose one DS overall  19 (1020/53) 28 (337/12) 18 (337/19) 16 (346/22) 0.171
Among those
Screened positive 31 (736/24) 44 (262/6) 26 (236/9) 27 (238/9)
Increased NT 4 (80/21) 2 (13/6) 5 (37/7) 4 (30/8)
Structural anomaly 28 (110/4) - (33/0) 19 (38/2) 20 (39/2)
NIPT high risk 1 (4/4) - 1 (1/1) 1 (3/3)
Abbreviations: DS = Down’s syndrome; IPD = invasive prenatal diagnosis; NIPT = non-invasive prenatal testing; NT = nuchal translucency
* Chi squared test for linear trend
† In two cases (one in 2011-12, the other in 2012-13), women declined IPD despite a positive DS screening result. In another two cases (one in 2010-11, 
and the other in 2011-12), women chose to continue their pregnancy after IPD of DS
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who had a positive aneuploidy screening but a low-
risk NIPT result underwent IPD and had normal 
fetal karyotype. There were no false-negative results 
and all babies were confirmed normal after delivery 
by routine clinical examination. 
Performance of conventional screening
The overall screen-positive and false-positive rates 
were 6.8% and 6.5% respectively, and were similar 
over the 3-year period (Table 1). 
 With an increasing number of NIPT as 
secondary screening performed for positive cFTS/
STS, the false-positive rate of screening decreased 
from 6.9% in 2010-11 to 5.2% in 2011-12 and 4.9% 
in 2012-13. In 2012-13, with 107 NIPT performed 
for a positive cFTS or STS, the false-positive rate 
decreased by 29.0% from 6.9% to 4.9%. 
 The cFTS risk of the five cases of Down’s 
syndrome not diagnosed prenatally was 1 in 300, 690, 
770, 7300, and 7300. In other words, the risk of three 
out of these five cases was below 1 in 1000. All five 
women were younger than 35 years. Among those 
screened negative, four cases of Down’s syndrome 
were diagnosed prenatally by IPD performed for 
fetal anomaly (Fig). In one of these four cases, mid-
trimester scan showed subtle sonographic signs 
including absent nasal bone and persistent left 
superior vena cava. 
Discussion
As shown in other studies5,14 and our previous study,16 
the introduction of NIPT was accompanied by a 
decrease in IPD rate. In the present study, we have 
further shown that the introduction of NIPT reduced 
the IPD rate for positive aneuploidy screening 
without affecting the prenatal detection of Down’s 
syndrome. Consistent with previous studies,5,13,14 
there was a rapid uptake of NIPT, probably because 
of its non-invasive nature and high sensitivity and 
specificity for common aneuploidies.6 A local study 
showed that NIPT results could reduce women’s 
uncertainty associated with risk probability–based 
results from conventional screening.18 Women are 
willing to pay for a test that has a lower false-positive 
rate.19
 We could not exclude the possibility that the 
reduction in IPD rate might be partially related to 
an increase in the proportion of cFTS with a lower 
FIG.  Number of fetuses and newborns with DS diagnosed prenatally or postnatally according to different screening tests
Abbreviations: cFTS = combined first-trimester screening; DS = Down’s syndrome; IPD = invasive prenatal diagnosis; NIPT = 
non-invasive prenatal testing; NT = nuchal translucency; STS = second-trimester screening
16 098 Pregnancies underwent DS screening
466 Had no conventional screening15 632 Had conventional screening
 (cFTS or STS)
1069 Screened positive or had 
increased NT
14 563 Screened negative 90 Had 
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false-positive rate than STS.3 Nevertheless, we 
observed no significant increase in IPD performed 
for structural anomalies despite a concern about 
missing atypical chromosomal abnormalities with 
NIPT alone.17,20,21
 The benefit of reducing the IPD rate is 
particularly relevant to our screening programme as 
the overall screen-positive rate of our conventional 
screening programme was 6.8%, which is higher 
than the published figures of 3.3% to 5.9%.4,22-26 With 
increasing use of NIPT as secondary screening for 
a positive result of cFTS/STS, the false-positive rate 
was reduced. The improvement was encouraging 
even before full implementation of the strategy using 
NIPT as a secondary screening tool. 
 Assuming 1.8% reduction in IPD (7.6% in 
2010-11 – mean of 5.7% in 2011-12 and 6.0% in 2012-
13; Table 1) as in our present study, an annual delivery 
rate of 50 000 in Hong Kong, and 1% miscarriage 
rate associated with IPD, we estimate that around 
900 IPDs or nine miscarriages can be potentially 
avoided if this contingent approach is adopted 
widely. This reduction in IPD-related miscarriage 
could be further improved as theoretically about 
98% of the IPD for positive aneuploidy screening 
could be avoided if NIPT was used by all screen-
positive women.27 Nonetheless, 1.8% ([1020-
736]/16 098) of IPD (Table 2) were still required 
for other indications including increased NT or 
structural anomalies, even if all screen-positive 
women opted for NIPT. Alternatively, the screen-
positive rate could be reduced by changing the 
cut-off value from 1 in 250 to 1 in 150,2 improving 
the quality assurance of measurement of NT (www.
fetalmedicine.com) and laboratory assays of serum 
markers, algorithms in calculation of trisomy 21 
risk, and adding sonographic markers.4,28
 The prenatal detection rate of Down’s syndrome 
in the present study was similar to the published 
results of 83% to 93%.4,22-26 In contrast to cFTS and 
STS that have been used in primary screening and 
resulted in a reduction in the number of live births 
with Down’s syndrome,1,4 introduction of NIPT did 
not improve the detection rate of our screening 
programme. This is expected as NIPT is currently not 
routinely used for primary screening. Nevertheless, 
NIPT did not decrease the detection rate of Down’s 
syndrome as there was no false-negative rate for 
NIPT in the present small study. There was concern 
about missing atypical abnormalities with NIPT 
alone.17,20,21 Further studies are required. 
 In keeping with international guidelines,29-32 
we suggest offering NIPT as an option to women 
with positive aneuploidy screening alone without 
increased NT or structural abnormalities to avoid an 
unnecessary IPD and its associated miscarriage risk. 
We also recommend improving the prenatal detection 
rate of a screening programme for Down’s syndrome 
by adjusting the cut-off value for cFTS, for example, 
from 1 in 250 to 1 in 1000, rather than offering it 
to all women as a primary screening.33 In our unit, 
the detection rate would be improved from 91.4% to 
96.6% as cFTS risk of three of our five missed cases 
of Down’s syndrome were above 1 in 1000. As such, 
NIPT would be offered to 16.9% of women, including 
6.8% with cFTS risk ≥1 in 250 and 10.1% with risk 
>1 in 1000 but <1 in 250. Offering an additional 
option of NIPT to women with advanced maternal 
age only did not improve the detection rate based 
on the results of the present study, probably because 
all five missed cases were younger than 35 years and 
sample size was small. Careful analysis with accurate 
assumptions, including the uptake rate of cFTS, 
and NIPT, the number of IPD avoided, cut-off value 
for cFTS, decreasing charges of NIPT with time,34 
and other issues is required to determine the cost-
effectiveness of incorporating NIPT into the current 
screening programme for Down’s syndrome.20,35 
Major governing or professional bodies recommend 
NIPT in the context of informed consent, education, 
and pre- and post-test counselling.29-32,36 In our 
previous study,37 we showed that Chinese women 
who underwent NIPT recognised the limitations, 
but did not understand the complicated aspects. 
We suggest giving more information by health care 
professionals, preferably trained midwives, so that 
patients can make an informed choice.37
 The limitations of the present study included 
its retrospective nature, single-centre, and small 
sample size. The actual performance of NIPT could 
not be examined as not all eligible subjects were 
tested. Availability and payment methods for NIPT 
and other prenatal testing, cut-off level of cFTS, and 
women’s preferences differ in different places. Thus, 
generalisation of the results of the present study 
should be done with caution.
Conclusion
The introduction of NIPT as a contingent approach 
reduced the IPD rate for positive aneuploidy 
screening without increasing the IPD rate for scan 
abnormalities or affecting the overall prenatal 
detection rate of Down’s syndrome. This fall in IPD 
rate was particularly relevant in our centre with a 
high false-positive rate after cFTS. 
Acknowledgements
We would like to thank the prenatal diagnostic 
laboratory of Tsan Yuk Hospital and Prince of 
Wales Hospital, Hong Kong for performing the 
chromosome analysis. 
Declaration
All authors have disclosed no conflicts of interest.
#  Prenatal testing for Down’s syndrome  # 
229Hong Kong Med J  ⎥  Volume 22 Number 3  ⎥  June 2016  ⎥  www.hkmj.org
References
1. Cheffins T, Chan A, Haan EA, et al. The impact of maternal 
serum screening on the birth prevalence of Down's 
syndrome and the use of amniocentesis and chorionic 
villus sampling in South Australia. BJOG 2000;107:1453- 
9.
2. Morgan S, Delbarre A, Ward P. Impact of introducing a 
national policy for prenatal Down syndrome screening 
on the diagnostic invasive procedure rate in England. 
Ultrasound Obstet Gynecol 2013;41:526-9.
3. Muller PR, Cocciolone R, Haan EA, et al. Trends in state/
population-based Down syndrome screening and invasive 
prenatal testing with the introduction of first-trimester 
combined Down syndrome screening, South Australia, 
1995-2005. Am J Obstet Gynecol 2007;196:315.e1-7; 
discussion 285-6.
4. Ekelund CK, Jørgensen FS, Petersen OB, Sundberg K, 
Tabor A; Danish Fetal Medicine Research Group. Impact 
of a new national screening policy for Down’s syndrome 
in Denmark: population based cohort study. BMJ 
2008;337:a2547. 
5. Chetty S, Garabedian MJ, Norton ME. Uptake of 
noninvasive prenatal testing (NIPT) in women following 
positive aneuploidy screening. Prenat Diagn 2013;33:542-
6.
6. Norton ME, Brar H, Weiss J, et al. Non-Invasive 
Chromosomal Evaluation (NICE) Study: results of a 
multicenter prospective cohort study for detection of 
fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 
2012;207:137.e1-8.
7. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et 
al. DNA sequencing of maternal plasma to detect Down 
syndrome: an international clinical validation study. Genet 
Med 2011;13:913-20.
8. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert 
AJ, Rava RP; MatErnal BLood IS Source to Accurately 
diagnose fetal aneuploidy (MELISSA) Study Group. 
Genome-wide fetal aneuploidy detection by maternal 
plasma DNA sequencing. Obstet Gynecol 2012;119:890-
901.
9. Evans MI, Wright DA, Pergament E, Cuckle HS, Nicolaides 
KH. Digital PCR for noninvasive detection of aneuploidy: 
power analysis equations for feasibility. Fetal Diagn Ther 
2012;31:244-7. 
10. Malone FD, Canick JA, Ball RH, et al. First-trimester or 
second-trimester screening, or both, for Down’s syndrome. 
N Engl J Med 2005;353:2001-11.
11. Wald NJ. Prenatal screening for open neural tube defects 
and Down syndrome: three decades of progress. Prenat 
Diagn 2010;30:619-21.
12. Rozenberg P, Bussières L, Chevret S, et al. Screening for 
Down syndrome using first-trimester combined screening 
followed by second-trimester ultrasound examination 
in an unselected population. Am J Obstet Gynecol 
2006;195:1379-87.
13. Larion S, Romary L, Mlynarczyk M, Abuhamad AZ, Warsof 
SL. Changes in prenatal testing trends after introduction 
of noninvasive prenatal testing. Obstet Gynecol 2014;123 
Suppl 1:62S-63S. 
14. Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, 
Abuhamad AZ. Uptake of noninvasive prenatal testing 
at a large academic referral center. Am J Obstet Gynecol 
2014;211:651.e1-7.
15. Musci TJ, Fairbrother G, Batey A, Bruursema J, Struble C, 
Song K. Non-invasive prenatal testing with cell-free DNA: 
US physician attitudes toward implementation in clinical 
practice. Prenat Diagn 2013;33:424-8.
16. Poon CF, Tse WC, Kou KO, Leung KY. Uptake of non-
invasive prenatal testing in Chinese women following 
positive Down syndrome screening. Fetal Diagn Ther 
2015;37:141-7.
17. Petersen OB, Vogel I, Ekelund C, Hyett J, Tabor A; 
Danish Fetal Medicine Study Group; Danish Clinical 
Genetics Study Group. Potential diagnostic consequences 
of applying non-invasive prenatal testing: population-
based study from a country with existing first-trimester 
screening. Ultrasound Obstet Gynecol 2014;43:265-71. 
18. Yi H, Hallowell N, Griffiths S, Yeung Leung T. Motivations 
for undertaking DNA sequencing-based non-invasive 
prenatal testing for fetal aneuploidy: a qualitative study 
with early adopter patients in Hong Kong. PLoS One 
2013;8:e81794.
19. Lo TK, Lai FK, Leung WC, et al. Screening options for 
Down syndrome: how women choose in real clinical 
setting. Prenat Diagn 2009;29:852-6.
20. van Landingham S, Bienstock J, Wood Denne E, Hueppchen 
N. Beyond the first trimester screen: can we predict who 
will choose invasive testing? Genet Med 2011;13:539-44.
21. Benn P, Borell A, Chiu R, et al. Position statement from the 
Aneuploidy Screening Committee on behalf of the Board 
of the International Society for Prenatal Diagnosis. Prenat 
Diagn 2013;33:622-9.
22. Hadlow NC, Hewitt BG, Dickinson JE, Jacoby P, Bower 
C. Community-based screening for Down’s Syndrome in 
the first trimester using ultrasound and maternal serum 
biochemistry. BJOG 2005;112:1561-4.
23. O’Leary P, Breheny N, Dickinson JE, et al. First-trimester 
combined screening for Down syndrome and other fetal 
anomalies. Obstet Gynecol 2006;107:869-76.
24. Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, 
Scharf A. Screening for trisomy 21 with maternal age, fetal 
nuchal translucency and maternal serum biochemistry at 
11-14 weeks: a regional experience from Germany. Fetal 
Diagn Ther 2006;21:264-8.
25. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides 
KH. Screening for chromosomal abnormalities in the 
first trimester using ultrasound and maternal serum 
biochemistry in a one-stop clinic: a review of three years 
prospective experience. BJOG 2003;110:281-6.
26. Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron 
AD, Connor JM. First-trimester combined ultrasound and 
biochemical screening for Down syndrome in routine 
clinical practice. Prenat Diagn 2004;24:774-80.
27. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive 
prenatal assessment of trisomy 21 by multiplexed maternal 
plasma DNA sequencing: large scale validity study. BMJ 
2011;342:c7401.
28. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 
weeks. Prenat Diagn 2011;31:7-15.
29. American College of Obstetricians and Gynecologists 
Committee on Genetics. Committee Opinion No. 545: 
Noninvasive prenatal testing for fetal aneuploidy. Obstet 
Gynecol 2012;120:1532-4. 
30. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on 
noninvasive prenatal screening for fetal aneuploidy. Genet 
Med 2013;15:395-8.
  #  Kou et al #
230 Hong Kong Med J  ⎥  Volume 22 Number 3  ⎥  June 2016  ⎥  www.hkmj.org
31. Soothill PW, Lo YM. Non-invasive prenatal testing for 
chromosomal abnormality using maternal plasma DNA, 
Scientific Impact Paper No. 15. London, Royal College of 
Obstetricians and Gynaecologists; 2014.
32. Benn P, Borrell A, Chiu R, et al. Position Statement from 
the Chromosome Aneuploidy Screening Committee 
on behalf of the Board of the International Society for 
Prenatal Diagnosis. April 2015. Available from: https://
www.ispdhome.org/docs/ISPD/Society%20Statements/
PositionStatement_Current_8Apr2015.pdf. Accessed 8 
Oct 2015.
33. Benn P, Curnow KJ, Chapman S, Michalopoulos SN, 
Hornberger J, Rabinowitz M. An economic analysis of cell-
free DNA non-invasive prenatal testing in the US general 
pregnancy population. PLoS One 2015;10:e0132313. 
34. Shengmou L, Min C, Chenhong W, et al. Effects, safety 
and cost-benefit analysis of Down syndrome screening in 
first trimester [in Chinese]. Zhonghua Fu Chan Ke Za Zhi 
2014;49:325-30.
35. Stoll K, Lutgendorf M, Knutzen D, Nielsen PE. Questioning 
the costs and benefits of non-invasive prenatal testing. J 
Matern Fetal Neonatal Med 2014;27:633-4.
36. Devers PL, Cronister A, Ormond KE, Facio F, Brasington 
CK, Flodman P. Noninvasive prenatal testing/noninvasive 
prenatal diagnosis: the position of the National Society of 
Genetic Counselors. J Genet Couns 2013;22:291-5. 
37. Kou KO, Poon CF, Tse WC, Mak SL, Leung KY. Knowledge 
and future preference of Chinese omen in a major public 
hospital in Hong Kong after undergoing non-invasive 
prenatal testing for positive aneuploidy screening: 
a questionnaire survey. BMC Pregnancy Childbirth 
2015;15:199. 
